Zacks Research Analysts Cut Earnings Estimates for PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research dropped their Q2 2025 earnings estimates for Puma Biotechnology in a research report issued on Wednesday, April 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.08 for the quarter, down from their previous estimate of $0.09. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's FY2025 earnings at $0.48 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.02 EPS.

Several other analysts have also issued reports on PBYI. StockNews.com lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Trading Down 1.8 %

PBYI stock traded down $0.06 during trading on Friday, reaching $2.93. 170,649 shares of the stock were exchanged, compared to its average volume of 439,080. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $145.17 million, a price-to-earnings ratio of 6.09 and a beta of 1.29. The business has a 50 day moving average price of $3.13 and a 200-day moving average price of $3.04. Puma Biotechnology has a 1 year low of $2.23 and a 1 year high of $5.20.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $59.10 million for the quarter, compared to analysts' expectations of $52.50 million.

Institutional Trading of Puma Biotechnology

A number of large investors have recently modified their holdings of PBYI. Acorn Capital Advisors LLC purchased a new stake in Puma Biotechnology during the 4th quarter worth about $7,475,000. Kennedy Capital Management LLC raised its holdings in Puma Biotechnology by 36.5% in the fourth quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock valued at $2,469,000 after acquiring an additional 216,329 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Puma Biotechnology by 24.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock worth $2,635,000 after acquiring an additional 170,968 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in Puma Biotechnology by 287.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 222,608 shares of the biopharmaceutical company's stock worth $679,000 after acquiring an additional 165,220 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Puma Biotechnology by 266.2% in the 4th quarter. Two Sigma Investments LP now owns 181,471 shares of the biopharmaceutical company's stock valued at $553,000 after purchasing an additional 131,916 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.